Objective: To observe the therapeutic effect of alprostadil combined with ganglioside on acute cerebral infarction. Methods: A total of 96 patients with acute ischemic stroke patients were enrolled from January 2010 to December 2013 for the present study. All patients were randomly assigned into a combined therapy group (n=50) and a control group (n=46). The patients in the control group were treated with ganglioside for 2 weeks, while those in the combined therapy group received alprostadil plus ganglioside for 2 weeks. At the end of experiments, the therapeutic effect, score of neurological deficits, activities of daily living score and cognitive function by MoCA were evaluated and compared. Results: The number of overall efficacy in the combined therapy group was more than that in the control group (47 vs 34, P<0.01). The score of neurological deficit was significantly lower in the combined therapy group than that in the control group; the activities of daily living score and cognitive function were significantly higher in the combined therapy group than those in the control group. Conclusion: Alprostadil combined with ganglioside in treatment of acute cerebral infarction displays advantages over ganglioside treatment alone.